olivLaw · US equity research
Avantor, Inc. AVTR
Laboratory Analytical Instruments · SIC 3826 · Vertical: Laboratory Analytical Instruments (SIC 3826)
Avantor is a global provider of mission-critical products and services for laboratories, biopharma and advanced technology customers, with a significant share of recurring sales. Sales declined slightly in 2025, and in the second quarter of 2026 the company reported a recovery in its VWR distribution segment, which could support performance if the trend holds. The company runs a cost-reduction program and carries significant gross debt, both relevant to assessing its current position.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Avantor, Inc. (AVTR) stock was 15.65 USD (+0.38% on the day), with market capitalisation 10.6 bn USD, P/E 31.5 on diluted EPS of 0.50 USD over the last 12 months, beta 1.03, 52-week range 7.41–17.29 USD. Latest reported quarter (Q3 2026): revenue of 1.7 bn USD (+4.6% YoY), net income of 203.4 m USD, diluted EPS 0.30 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 44.0
- weak (30–45)
- Bollinger (20, 2)
- 14.94 – 17.62
- in the lower half of the band · %B 0.27 · band width 16.5%
- SMA 50 / 200
- 15.56 / 11.27
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.16 / 0.36
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −1.0% | −1.1% | +0.1 pp | — |
| 3 months | +17.1% | −0.5% | +17.6 pp | — |
| 6 months | +85.6% | +4.4% | +81.3 pp | — |
| Year to date | +36.6% | +12.3% | +24.2 pp | — |
| 1 year | +35.1% | +13.5% | +21.6 pp | +14.4% |
| 3 years | −14.8% | +76.4% | −91.2 pp | +1.8% |
| 5 years | −59.0% | +63.7% | −122.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7 bn | 1.6 bn | 1.7 bn | 1.6 bn | 1.7 bn | 1.6 bn | 1.7 bn | 1.7 bn |
| Cost of revenue | 1.1 bn | 1.0 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.2 bn | 1.2 bn |
| Gross profit | 562.9 m | 534.9 m | 554.1 m | 526.5 m | 523.9 m | 500.7 m | 537.0 m | 534.8 m |
| SG&A | 371.4 m | 387.5 m | 425.3 m | 390.3 m | 392.4 m | 401.2 m | 415.2 m | 395.3 m |
| Operating income | 638.1 m | 147.4 m | 128.8 m | -648.8 m | 126.4 m | 99.5 m | 121.8 m | 139.5 m |
| Depreciation & amortisation | 100.9 m | 99.7 m | 102.7 m | 104.5 m | 103.3 m | 105.0 m | 105.6 m | 105.3 m |
| Interest expense | 44.9 m | 42.2 m | 43.4 m | 44.2 m | 40.0 m | 42.9 m | 39.4 m | 39.9 m |
| Pre-tax income | 584.2 m | 85.7 m | 81.7 m | -689.5 m | 80.8 m | 55.5 m | 81.2 m | 98.0 m |
| Income tax | 83.8 m | 21.2 m | 17.0 m | 22.3 m | 28.4 m | 12.2 m | 43.1 m | -105.4 m |
| Net income | 500.4 m | 64.5 m | 64.7 m | -711.8 m | 52.4 m | 43.3 m | 38.1 m | 203.4 m |
| Diluted EPS | 0.73 ≈ | 0.09 | 0.09 | -1.04 | 0.08 ≈ | 0.06 | 0.06 | 0.30 |
| Operating cash flow | 173.3 m | 109.3 m | 154.4 m ≈ | 207.4 m ≈ | 152.7 m | 58.7 m | 178.2 m ≈ | 195.1 m ≈ |
| Capex | 27.5 m | 28.0 m | 29.6 m ≈ | 35.7 m ≈ | 35.5 m | 33.5 m | 37.6 m ≈ | 38.9 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 32 percentile of its own 22-quarter history (min 13.5, median 39.4, max 312.8; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.9 bn | 6.0 bn | 6.4 bn | 7.4 bn | 7.5 bn | 7.0 bn | 6.8 bn | 6.6 bn |
| Revenue YoY | +370.1% | +3.0% | +5.8% | +15.5% | +1.7% | −7.3% | −2.6% | −3.4% |
| Net income | -86.9 m | 37.8 m | 116.6 m | 572.6 m | 686.5 m | 321.1 m | 711.5 m | -530.2 m |
| Net income YoY | unavailable | unavailable | +208.5% | +391.1% | +19.9% | −53.2% | +121.6% | −174.5% |
| Diluted EPS | -2.69 | -0.84 | 0.09 | 0.85 | 1.01 | 0.47 | 1.04 | -0.78 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | +844.4% | +18.8% | −53.5% | +121.3% | −175.0% |
| net % | -1.5% | 0.6% | 1.8% | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% |
| Free cash flow | 162.8 m | 302.4 m | 868.2 m | 842.5 m | 710.2 m | 723.6 m | 692.0 m | 495.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 365.4 m USD
- Financial debt
- 3.9 bn USD
- Net debt
- 3.6 bn USD
- Equity
- 5.6 bn USD
- Total assets
- 11.8 bn USD
- Debt / equity
- 0.71x
- Current ratio
- 1.78x
- ROE
- -9.2%
- ROA
- -4.4%
- FCF margin
- 7.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 6.4 bn | 7.4 bn | 7.5 bn | 7.0 bn | 6.8 bn | 6.6 bn | SEC (XBRL)· 11 Feb 2026verified |
| Cost of revenue | 4.3 bn | 4.9 bn | 4.9 bn | 4.6 bn | 4.5 bn | 4.4 bn | SEC (XBRL)· 11 Feb 2026verified |
| Gross profit | 2.1 bn | 2.5 bn | 2.6 bn | 2.4 bn | 2.3 bn | 2.1 bn | SEC (XBRL)· 11 Feb 2026verified |
| SG&A | 1.4 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.6 bn | 1.6 bn | SEC (XBRL)· 11 Feb 2026verified |
| Operating income | 706.8 m | 972.2 m | 1.1 bn | 696.4 m | 1.1 bn | -246.2 m | SEC (XBRL)· 11 Feb 2026verified |
| Depreciation & amortisation | 395.4 m | 379.2 m | 405.5 m | 402.3 m | 405.5 m | 410.2 m | SEC (XBRL)· 11 Feb 2026verified |
| EBITDA | 1.1 bn ≈ | 1.4 bn ≈ | 1.5 bn ≈ | 1.1 bn ≈ | 1.5 bn ≈ | 164.0 m ≈ | SEC (XBRL)· 11 Feb 2026derived |
| Interest expense | 307.6 m | 217.4 m | 265.8 m | 284.8 m | 218.8 m | 169.8 m | SEC (XBRL)· 11 Feb 2026verified |
| Pre-tax income | 62.3 m | 753.0 m | 851.1 m | 410.5 m | 853.9 m | -441.3 m | SEC (XBRL)· 11 Feb 2026verified |
| Income tax | -54.3 m | 180.4 m | 164.6 m | 89.4 m | 142.4 m | 88.9 m | SEC (XBRL)· 11 Feb 2026verified |
| Net income | 116.6 m | 572.6 m | 686.5 m | 321.1 m | 711.5 m | -530.2 m | SEC (XBRL)· 11 Feb 2026verified |
| Diluted EPS | 0.09 | 0.85 | 1.01 | 0.47 | 1.04 | -0.78 | SEC (XBRL)· 11 Feb 2026verified |
| Weighted average diluted shares | 583.4 m | 599.6 m | 679.4 m | 678.4 m | 681.9 m | 680.6 m | SEC (XBRL)· 11 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 286.6 m | 301.7 m | 372.9 m | 262.9 m | 261.9 m | 365.4 m | SEC (XBRL)· 11 Feb 2026verified |
| Receivables | 1.1 bn | 1.2 bn | 1.2 bn | 1.2 bn | 1.0 bn | 1.1 bn | SEC (XBRL)· 11 Feb 2026verified |
| Inventories | 739.6 m | 872.0 m | 913.5 m | 828.1 m | 731.5 m | 818.2 m | SEC (XBRL)· 11 Feb 2026verified |
| Current assets | 2.2 bn | 2.5 bn | 2.7 bn | 2.4 bn | 2.1 bn | 2.5 bn | SEC (XBRL)· 11 Feb 2026verified |
| Property, plant & equipment, net | 549.9 m | 705.5 m | 727.0 m | 737.5 m | 708.1 m | 766.8 m | SEC (XBRL)· 11 Feb 2026verified |
| Goodwill | 2.9 bn | 5.3 bn | 5.7 bn | 5.7 bn | 5.5 bn | 5.0 bn | SEC (XBRL)· 29 Apr 2026verified |
| Intangibles (excl. goodwill) | 4.0 bn | 5.0 bn | 4.0 bn | 3.7 bn | 3.3 bn | 3.1 bn | SEC (XBRL)· 11 Feb 2026verified |
| Total assets | 9.9 bn | 13.9 bn | 13.5 bn | 13.0 bn | 12.1 bn | 11.8 bn | SEC (XBRL)· 11 Feb 2026verified |
| Accounts payable | 678.9 m | 755.1 m | 758.2 m | 625.9 m | 662.8 m | 741.7 m | SEC (XBRL)· 11 Feb 2026verified |
| Short-term debt | 26.4 m | 45.2 m | 364.2 m | 259.9 m | 821.1 m | 30.8 m | SEC (XBRL)· 11 Feb 2026verified |
| Long-term debt | 4.9 bn | 7.0 bn | 5.9 bn | 5.3 bn | 3.2 bn | 3.9 bn | SEC (XBRL)· 11 Feb 2026verified |
| Current liabilities | 1.2 bn | 1.5 bn | 1.7 bn | 1.5 bn | 2.0 bn | 1.4 bn | SEC (XBRL)· 11 Feb 2026verified |
| Total liabilities | 7.2 bn | 9.7 bn | 8.6 bn | 7.7 bn | 6.2 bn | 6.2 bn | SEC (XBRL)· 11 Feb 2026verified |
| Equity | 2.7 bn † | 4.2 bn † | 4.9 bn † | 5.3 bn † | 6.0 bn † | 5.6 bn † | SEC (XBRL)· 11 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 929.8 m | 953.6 m | 843.6 m | 870.0 m | 840.8 m | 623.8 m | SEC (XBRL)· 11 Feb 2026verified |
| Capex | 61.6 m | 111.1 m | 133.4 m | 146.4 m | 148.8 m | 128.8 m | SEC (XBRL)· 11 Feb 2026verified |
| Free cash flow | 868.2 m ≈ | 842.5 m ≈ | 710.2 m ≈ | 723.6 m ≈ | 692.0 m ≈ | 495.0 m ≈ | SEC (XBRL)· 11 Feb 2026derived |
| Investing cash flow | -59.1 m | -4.1 bn | -109.6 m | -143.7 m | 438.9 m | -130.5 m | SEC (XBRL)· 11 Feb 2026verified |
| Financing cash flow | -782.9 m | 3.2 bn | -648.7 m | -843.7 m | -1.3 bn | -409.4 m | SEC (XBRL)· 11 Feb 2026verified |
| Share repurchases | — | — | — | 0 | 0 | 75.1 m | SEC (XBRL)· 11 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 47 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 10.6 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation45
- Returns10
- Quality93
- Balance sheet32
- Growth0
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 5.69 – 19.30 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)5.69 – 12.47 (Mid 8.19)WACC 8.2% · starting FCFF 575.4 m USD · terminal value share of EV 76%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 15.6%
- Peers: EV/EBITDAunavailable · not enough peers
- Peers: P/E18.33 – 19.30 (Mid 19.29)3 companies used · median multiple 38.8x · quartiles 36.9x – 38.8xA, ILMN, MTD
- Dividend discount (DDM)unavailable · input data missing
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 47/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 4.5% | 100 (vs peers) | 12% |
| Net margin · Quality | 5.1% | 74 (vs peers) | 7% |
| FCF conversion · Quality | 130.2% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | -4.5% | 0 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 3.6x | 13 (on a fixed band) | 12% |
| Interest coverage · Balance sheet | 3.0x | 23 (on a fixed band) | 7% |
| Current ratio · Balance sheet | 1.9x | 91 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 31.5x | 83 (vs peers) | 12% |
| EV/EBITDA · Valuation | 15.3x | 0 (on a fixed band) | 12% |
| FCF yield · Valuation | 4.1% | 52 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | 0.7% | 10 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet32/100 · 3/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality93/100 · 3/3 factors with a value
- Returns· partial10/100 · 1/2 factors with a value
- Valuation45/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Avantor, Inc. (AVTR). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 6.6 bn USD in 2025; YoY growth -3.4%; net margin 5.1%; ROE 5.9%; net debt/EBITDA 3.6x.
The estimated value range is 12.01–15.89 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 13.74 USD, the price of 15.65 USD leaves a potential of -12.2% (value / price − 1) and a margin of safety of -13.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 47/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 4.5%
- Net margin: 5.1%
- FCF conversion: 130.2%
- Current ratio: 1.9x
- P/E (TTM): 31.5x
What contradicts it
- Revenue CAGR 3Y: -4.5%
- Net debt / EBITDA: 3.6x
- Interest coverage: 3.0x
- EV/EBITDA: 15.3x
- Shareholder yield (distributions): 0.7%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): EPS CAGR 3Y, Payout ratio (FCF).
Versus the vertical median
Laboratory Analytical Instruments (SIC 3826) · same industry (4-digit SIC) · compared with 20 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | 49.9 bn | 34.9 | 21.0% | 19.5% | +6.7% | +15% / +39% |
| WATWaters Corporation | 45.9 bn | 116.6 | 1.9% | 3.6% | +7.0% | +16% / +67% |
| MTDMettler-Toledo International Inc. | 34.5 bn | 38.8 | — | 21.9% | +4.0% | +17% / +58% |
| ILMNIllumina, Inc. | 34.3 bn | 38.8 | 32.4% | 19.7% | −0.7% | +72% / +128% |
| RVTYRevvity, Inc | 17.8 bn | 76.0 | 3.2% | 8.2% | +3.7% | +53% / +79% |
| AVTRAvantor, Inc. | 10.6 bn | 31.5 | 5.9% | 5.1% | −3.4% | +35% / −15% |
| BRKRBruker Corporation | 9.7 bn | — | -3.4% | -2.0% | +2.1% | +31% / −2% |
| TXG10x Genomics, Inc. | 8.6 bn | — | -9.4% | -12.2% | +5.2% | +259% / +55% |
| PACBPacific Biosciences of California, Inc. | 792.6 m | — | -929.3% | -82.5% | +3.9% | +10% / −70% |
| CTKBCytek Biosciences, Inc. | 769.0 m | — | -23.2% | -39.1% | +0.5% | +4% / −15% |
| MASS908 Devices Inc. | 457.6 m | — | -25.2% | -57.0% | +17.7% | +74% / +39% |
| NAUTNautilus Biotechnology, Inc. | 291.7 m | — | -41.0% | — | unavailable | +2% / −17% |
| QTRXQuanterix Corporation | 143.8 m | — | -46.5% | -80.2% | +1.1% | −58% / −87% |
| SEERSeer, Inc. | 94.1 m | — | -26.4% | -478.0% | +17.0% | −11% / +6% |
| HBIOHarvard Bioscience, Inc. | 39.2 m | — | -89.9% | -11.9% | −8.1% | +13% / −80% |
| PRPOPrecipio, Inc. | 35.0 m | — | -9.0% | -4.5% | +29.8% | −20% / +187% |
| EYPTEyePoint, Inc. | 34.1 m | — | -148.7% | -10,994.7% | −27.5% | −97% / −94% |
| BNGOBionano Genomics, Inc. | 14.0 m | — | -83.6% | -106.6% | −7.4% | −36% / −99% |
| ASTCAstrotech Corporation | 9.1 m | — | -75.4% | -1,580.2% | −8.7% | +41% / −44% |
| BIOBio-Rad Laboratories, Inc. | — | 10.0 | 14.3% | 39.5% | +0.7% | +17% / +25% |
| RPIDRapid Micro Biosystems, Inc. | — | — | -141.6% | -145.6% | +19.7% | −84% / −42% |
1- and 3-year price returns: for AVTR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 8.42 Total return -46% · Per year -46% | 14.96 Total return -4% · Per year -4% | 22.64 Total return 45% · Per year 45% |
| 3 years | 6.77 Total return -57% · Per year -24% | 13.66 Total return -13% · Per year -4% | 22.88 Total return 46% · Per year 14% |
| 5 years | 5.44 Total return -65% · Per year -19% | 12.47 Total return -20% · Per year -4% | 23.13 Total return 48% · Per year 8% |
- Exit P/E± 3.41
- Net margin± 2.39
- Annual revenue growth± 2.15
- Annual dilution± 0.20
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (28 Oct 2026 · results), 10-Q (28 Oct 2026).
In brief
Avantor is a global provider of mission-critical products and services for laboratories, biopharma and advanced technology customers, with a significant share of recurring sales. Sales declined slightly in 2025, and in the second quarter of 2026 the company reported a recovery in its VWR distribution segment, which could support performance if the trend holds. The company runs a cost-reduction program and carries significant gross debt, both relevant to assessing its current position.
SWOT
Strengths
- A broad portfolio, extensive global presence and a high share of recurring sales provide a stable revenue base and long-standing customer relationships.
- High-purity products and customized solutions, such as implant-grade silicone and bioprocessing chemicals, are hard to replace in regulated applications.
- The digital channel handles a major share of transactions, making purchasing easier for customers and integrating it with their processes.
Weaknesses
- High gross debt and adjusted leverage limit financial flexibility and the capacity to invest.
- Sales fell in 2025 amid weaker demand and a divestiture, and the net loss was affected by impairment.
- Gross margins were under pressure from inflation, freight costs and unfavorable product mix.
Opportunities
- If the cost-reduction program is fully delivered, margins could recover and cash flow could improve.
- Demand from cell and gene therapy and the semiconductor industry could open new sales lines for specialty products.
- The VWR recovery could continue if education and government customers resume purchasing.
Threats
- Lower public funding for research may lead university and government customers to postpone purchases.
- Intense competition and consolidation of large customers could reduce prices and cost market share.
- Changes in trade policy and currency swings could affect costs and reported results.
Risks
- Goodwill impairmenthigh
A further deterioration in market conditions or in the projections of the VWR Distribution unit could lead to a significant accounting impairment.
- High indebtednesshigh
Adjusted net debt and refinancing costs may limit flexibility and put pressure on cash flow.
- Dependence on research fundingmedium
Public research budgets are unpredictable, and delays can postpone customer orders.
- Inflation and cost pressuresmedium
Raw material, freight and labor costs may rise faster than prices, weighing on margins.
- Currency and trade risklow
Exchange rate moves and tariffs can change results the company reports in US dollars.
Investment thesis
What would need to be true (bull case)
- If the organic recovery in the VWR segment continues and the cost program is delivered, results could improve beyond the 2025 level.
- The proprietary products segment has high margins and long customer relationships, which can support free cash flow.
- The high share of recurring sales may offer a more predictable base for long-term planning.
What would break the thesis
- If demand from publicly funded research stays weak, sales could keep declining.
- High debt could limit strategic options and amplify the effect of a weak period of results.
- If pricing pressure from large customers persists, margins could remain below historical levels.
What to watch
- Organic growth of the VWR Distribution & Services segmentQ3 2026
- Delivery of the target of about 400 million USD in run-rate gross savings2027
- Goodwill impairment risk for the VWR Distribution unitnext 10-Q
- Achievement of the 500 to 550 million USD free cash flow guidance2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (28 Oct 2026 · results), 10-Q (28 Oct 2026).
The business
Avantor supplies mission-critical products and services to customers in biopharma and healthcare, education and government, and advanced technologies, covering activity from discovery to delivery. It reaches the market in two ways: through the VWR channel, which distributes consumables and equipment to laboratories worldwide, and through manufacturing of proprietary products such as high-purity chemicals, Masterflex tubing and pumps, and NuSil silicone. With more than 300000 customer locations in about 180 countries, the company bases its model on long-standing relationships and an extensive global presence 1.
Segments
VWR Distribution & Services
This segment distributes laboratory consumables, equipment and services, including procurement and stockroom management. In the second quarter of 2026 net sales were 1240.5 million USD, with positive organic growth, indicating a faster recovery than expected 23.
Bioscience & Medtech Products
This segment produces high-purity materials, implant-grade silicone and fluid handling systems, with higher margins than distribution. In the second quarter of 2026 net sales were 451.8 million USD, and the adjusted operating income margin reached 26.0% 3.
Market context
Avantor operates in the life sciences tools and consumables market, where demand depends on research funding, pharmaceutical investment and the development of biologic production. The company reports that a large part of its sales comes from customers with relationships of more than 15 years, which provides stability but also exposure to changes in public research budgets 1.
Trends
- Inflationary pressuresheadwind
The company reports inflationary pressures across all cost categories, which could continue to weigh on results if pricing and productivity measures prove insufficient 2.
- Cost-reduction programtailwind
The cost transformation initiative has been expanded, targeting run-rate gross savings of about 400 million USD by the end of 2027, which could support margins if fully delivered 1.
- Currency and trade exposuremixed
Movements of the US dollar against the euro and uncertainty in trade policy can influence reported results, although recent developments have eased some tariff pressures 2.
- Goodwill impairment risk in VWRheadwind
The limited margin between fair value and carrying value of the VWR Distribution unit could lead to a significant impairment if market conditions deteriorate further 2.
Competitive position
The market is competitive and fragmented, with regional companies that respond quickly to local needs and large multinationals with greater research and development resources. Consolidation of purchasing groups in biopharma has increased pricing pressure, and new low-cost competitors may intensify competition 1.
- Thermo Fisher ScientificTMO
Multinational laboratory instruments and consumables group with greater research and development resources, named in the source among large competitors.
- Fisher Scientific
Laboratory distributor competing directly with the VWR channel in consumables and equipment.
- Regional distribution companies
Local distributors that can respond faster to customers in particular regions, according to the risk factor discussion.
- Low-cost consumables suppliers
New entrants from low-cost manufacturing locations that can add pricing pressure.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Avantor Stock Has Strong Technical Momentum, But Make Sure Your Stop Losses Are TightYahoo Finance — News · 16 Sept 2026 · EN
The latest news item in our archive is from 16 Sept 2026; the newest SEC filing is from 03 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report03 Nov 2026Departure or appointment of officers · Financial statements and exhibits
- Quarterly report28 Oct 2026
- Current report28 Oct 2026Results of operations · Financial statements and exhibits
- Current report21 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report21 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report (amendment)27 Aug 2026Departure or appointment of officers · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report17 Jul 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report12 May 2026Shareholder vote · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Avantor, Inc. · 11 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Avantor, Inc. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Avantor, Inc. · 29 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.